Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more
Vetoquinol (VETO) - Net Assets
Latest net assets as of June 2025: €567.53 Million EUR
Based on the latest financial reports, Vetoquinol (VETO) has net assets worth €567.53 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€725.82 Million) and total liabilities (€158.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €567.53 Million |
| % of Total Assets | 78.19% |
| Annual Growth Rate | 11.0% |
| 5-Year Change | 54.89% |
| 10-Year Change | 98.95% |
| Growth Volatility | 6.85 |
Vetoquinol - Net Assets Trend (2004–2024)
This chart illustrates how Vetoquinol's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vetoquinol (2004–2024)
The table below shows the annual net assets of Vetoquinol from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €575.93 Million | +9.26% |
| 2023-12-31 | €527.11 Million | +8.76% |
| 2022-12-31 | €484.66 Million | +9.81% |
| 2021-12-31 | €441.35 Million | +18.70% |
| 2020-12-31 | €371.83 Million | -3.67% |
| 2019-12-31 | €385.98 Million | +6.31% |
| 2018-12-31 | €363.08 Million | +8.15% |
| 2017-12-31 | €335.73 Million | +6.08% |
| 2016-12-31 | €316.48 Million | +9.32% |
| 2015-12-31 | €289.49 Million | +7.86% |
| 2014-12-31 | €268.40 Million | +13.75% |
| 2013-12-31 | €235.96 Million | +3.48% |
| 2012-12-31 | €228.01 Million | +7.91% |
| 2011-12-31 | €211.29 Million | +14.66% |
| 2010-12-31 | €184.27 Million | +18.93% |
| 2009-12-31 | €154.95 Million | +13.05% |
| 2008-12-31 | €137.05 Million | +7.18% |
| 2007-12-31 | €127.87 Million | +15.05% |
| 2006-12-31 | €111.15 Million | +28.02% |
| 2005-12-31 | €86.82 Million | +21.63% |
| 2004-12-31 | €71.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vetoquinol's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 488.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €58.69 Million | 10.19% |
| Common Stock | €29.70 Million | 5.16% |
| Other Comprehensive Income | €446.32 Million | 77.51% |
| Other Components | €41.13 Million | 7.14% |
| Total Equity | €575.84 Million | 100.00% |
Vetoquinol Competitors by Market Cap
The table below lists competitors of Vetoquinol ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
V2 Retail Limited
NSE:V2RETAIL
|
$301.93 Million |
|
Industrie De Nora S.p.A.
LSE:0ABI
|
$301.96 Million |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
|
$301.97 Million |
|
Target Hospitality Corp
NASDAQ:TH
|
$302.19 Million |
|
MIDLAND STS BANCOR.DL-01
F:6HU
|
$301.84 Million |
|
Site Centers Corp
NYSE:SITC
|
$301.80 Million |
|
Xiamen Sunrise Wheel Group Co Ltd
SHE:002593
|
$301.71 Million |
|
Suzhou YourBest New-type Materials Co.Ltd.
SHE:301266
|
$301.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vetoquinol's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 527,013,000 to 575,840,000, a change of 48,827,000 (9.3%).
- Net income of 58,685,000 contributed positively to equity growth.
- Dividend payments of 10,058,000 reduced retained earnings.
- Share repurchases of 2,934,000 reduced equity.
- Other comprehensive income increased equity by 45,702,000.
- Other factors decreased equity by 42,568,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €58.69 Million | +10.19% |
| Dividends Paid | €10.06 Million | -1.75% |
| Share Repurchases | €2.93 Million | -0.51% |
| Other Comprehensive Income | €45.70 Million | +7.94% |
| Other Changes | €-42.57 Million | -7.39% |
| Total Change | €- | 9.26% |
Book Value vs Market Value Analysis
This analysis compares Vetoquinol's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.80x to 1.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €7.86 | €77.00 | x |
| 2006-12-31 | €9.98 | €77.00 | x |
| 2007-12-31 | €10.25 | €77.00 | x |
| 2008-12-31 | €11.02 | €77.00 | x |
| 2009-12-31 | €13.08 | €77.00 | x |
| 2010-12-31 | €15.48 | €77.00 | x |
| 2011-12-31 | €17.93 | €77.00 | x |
| 2012-12-31 | €19.21 | €77.00 | x |
| 2013-12-31 | €19.86 | €77.00 | x |
| 2014-12-31 | €22.62 | €77.00 | x |
| 2015-12-31 | €24.40 | €77.00 | x |
| 2016-12-31 | €26.69 | €77.00 | x |
| 2017-12-31 | €28.31 | €77.00 | x |
| 2018-12-31 | €30.66 | €77.00 | x |
| 2019-12-31 | €32.65 | €77.00 | x |
| 2020-12-31 | €31.43 | €77.00 | x |
| 2021-12-31 | €37.31 | €77.00 | x |
| 2022-12-31 | €40.96 | €77.00 | x |
| 2023-12-31 | €44.54 | €77.00 | x |
| 2024-12-31 | €48.82 | €77.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vetoquinol utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.19%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.88%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.29x
- Recent ROE (10.19%) is below the historical average (10.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 13.98% | 5.49% | 1.03x | 2.48x | €2.84 Million |
| 2005 | 14.33% | 6.33% | 0.98x | 2.30x | €3.76 Million |
| 2006 | 14.24% | 7.48% | 1.00x | 1.90x | €4.71 Million |
| 2007 | 14.58% | 7.99% | 1.02x | 1.79x | €5.86 Million |
| 2008 | 13.55% | 7.92% | 0.99x | 1.73x | €4.86 Million |
| 2009 | 11.75% | 7.08% | 0.91x | 1.83x | €2.72 Million |
| 2010 | 12.08% | 7.89% | 0.91x | 1.68x | €3.83 Million |
| 2011 | 10.74% | 7.99% | 0.89x | 1.51x | €1.57 Million |
| 2012 | 9.90% | 7.57% | 0.84x | 1.56x | €-227.60K |
| 2013 | 10.00% | 7.87% | 0.85x | 1.49x | €-10.80K |
| 2014 | 9.60% | 8.17% | 0.75x | 1.56x | €-1.07 Million |
| 2015 | 8.35% | 7.05% | 0.83x | 1.43x | €-4.79 Million |
| 2016 | 8.79% | 7.94% | 0.80x | 1.39x | €-3.81 Million |
| 2017 | 10.38% | 9.89% | 0.79x | 1.32x | €1.26 Million |
| 2018 | 9.99% | 9.85% | 0.79x | 1.28x | €-50.60K |
| 2019 | 7.40% | 7.22% | 0.77x | 1.32x | €-10.05 Million |
| 2020 | 5.17% | 4.50% | 0.66x | 1.74x | €-17.95 Million |
| 2021 | 14.25% | 12.06% | 0.83x | 1.42x | €18.73 Million |
| 2022 | 9.90% | 8.89% | 0.83x | 1.35x | €-462.10K |
| 2023 | 10.54% | 10.50% | 0.76x | 1.31x | €2.86 Million |
| 2024 | 10.19% | 10.88% | 0.72x | 1.29x | €1.10 Million |
Industry Comparison
This section compares Vetoquinol's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,126,188,333
- Average return on equity (ROE) among peers: 13.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vetoquinol (VETO) | €567.53 Million | 13.98% | 0.28x | $301.84 Million |
| Boiron SA (BOI) | $134.47 Million | 17.12% | 0.72x | $92.91 Million |
| Euroapi SAS (EAPI) | $1.11 Billion | -1.35% | 0.56x | $65.91 Million |
| Ipsen SA (IPN) | $2.13 Billion | 25.68% | 1.02x | $4.04 Billion |